Dermatological Adverse Reactions and Therapeutic Potential of Semaglutide, Liraglutide, and Tirzepatide: Analysis of UK Pharmacovigilance Data and Literature Review
August 2025
TLDR GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
The study examines the dermatological effects of GLP-1 receptor agonists (GLP-1RAs) like semaglutide, liraglutide, and tirzepatide, which are used for type 2 diabetes and weight management. These medications offer therapeutic benefits for inflammatory skin conditions such as psoriasis and hidradenitis suppurativa due to their anti-inflammatory properties. However, they are linked to adverse effects, including alopecia, with tirzepatide having the highest reports (140 cases). The UK MHRA reported 1,369 dermatological cases by May 2025. The study stresses the need for dermatologists to balance benefits against side effects, advocating for monitoring and patient counseling. Alopecia, often due to rapid weight loss, typically resolves within 6-12 months after stopping the medication. The document calls for larger trials to confirm the efficacy and safety of GLP-1RAs and to explore mechanisms behind rare immune-mediated reactions.
